Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 11/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704778 | 0.95 | KDM4E (0.43) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL4699778 | 0.92 | KDM4E (0.47) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL4699723 | 0.91 | KDM4E (0.44) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL4700708 | 0.90 | KDM4E (0.43) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL4702947 | 0.87 | ESR1 (0.43) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL4699735 | 0.86 | KDM4E (0.45) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL4699674 | 0.85 | KDM4E (0.44) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL4701446 | 0.85 | KDM4E (0.42) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL4700602 | 0.85 | KDM4E (0.48) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1884350 | 0.84 | KDM4E (0.60) | KDM4EGABRA1GABRG2GABRB3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648896-B1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INT (ES) | 2008-02-13 | — | — | EP | claimed |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | FERRER INTERNACIONAL S.A. (ES) | 2007-02-22 | — | — | US | claimed |
| EP-1648896-A1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| EP-1622893-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | Hideg, Kalman (HU) | 2006-02-08 | — | — | EP | claimed |
| WO-2005014596-A1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO `1,5-A! PYRIMIDINES | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | claimed |
| WO-2004096793-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | HIDEG KALMAN (HU) | 2004-11-11 | — | — | WO | claimed |
| EP-1648896-B1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INT (ES) | 2008-02-13 | — | — | EP | disclosed |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | FERRER INTERNACIONAL S.A. (ES) | 2007-02-22 | — | — | US | disclosed |
| EP-1648896-A1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| EP-1622893-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | Hideg, Kalman (HU) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005014596-A1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO `1,5-A! PYRIMIDINES | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004096793-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | HIDEG KALMAN (HU) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | GABRB1, GABRA1, GABRB2 | KDM4E 3514/4885GABRA1 2/4885GABRG2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.